Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Bladder Cancer
Patients with locally advanced transitional cell bladder cancer receive 3 cycles of
neoadjuvant gemcitabine/cisplatin before radical cystectomy.
Patients with histologically confirmed clinical stage T2-T4a, N0-2 bladder cancer are going
to be included. After CT scan of the thorax and abdomen plus MRI of the pelvis patient
Pathologic response rate will be assessed after surgery by the institutional pathologic
review. Safety is going to be assessed according to the National Cancer Institute Common
Toxicity Criteria (CTC,version 3.0).
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
pathologic response rate
evaluation of the pathologic response rate after 3 cycles of neoadjuvant gemcitabine/cisplatin at time of radical cystectomy
at time of surgery
Johannes Meran, M.D.
Barmherzige Brüder Vienna